<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309514</url>
  </required_header>
  <id_info>
    <org_study_id>NGN-9076</org_study_id>
    <nct_id>NCT03309514</nct_id>
  </id_info>
  <brief_title>Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease</brief_title>
  <official_title>Clinical Investigation of Transplantation of Neural Stem Cell-derived Neurons for the Treatment of Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroGeneration</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroGeneration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study to demonstrate the safety and efficacy of differentiated
      neurons-derived from adult CNS progenitors cells transplanted in selected patients with
      Parkinson's disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor UPDRS</measure>
    <time_frame>6 months</time_frame>
    <description>UPDRS Motor scale</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intracerebral microinjections</intervention_name>
    <description>Stereotactic delivery of cell suspension into basal ganglia structures</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to give informed consent prior to study

          2. Male or Female with Diagnostic Criteria of Parkinson's disease

          3. Age 35 to 85 years old

          4. Parkinson's disease not due to trauma, infection, brain tumor, cerebrovascular disease

          5. Hoehn and Yahr Stage III or IV

          6. Parkinson's disease observed in the absence of:

               -  Oculomotor palsy

               -  Cerebellar sign

               -  Orthostatic hypotension (drop greater than 20mmHg in mean pressure)

               -  Pyramidal sign

               -  Amyotrophy

          7. Good general health or stable medical condition well controlled, without
             contraindications to anesthesia

        Exclusion Criteria:

          1. Patients with severe dementia and brain atrophy on MRI

          2. Patients with severe hypertension; renal, liver, cardiac or other major organ disease;
             coagulopathy; cancer; other significant systemic illnesses; hepatitis, HIV

          3. Patients older than 85 or younger than 35

          4. Patients who withhold informed consent

          5. Patients with a history of alcohol or drug abuse

          6. Sexually active women of childbearing potential without adequate form of birth control

          7. Evidence of abnormal coagulation or anticoagulant therapy

          8. Pregnancy or lactation

          9. History of seizure disorders or current use of antiepileptic medication

         10. Severe cognitive impairment

         11. Clinically significant laboratory abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NeuroGeneration</investigator_affiliation>
    <investigator_full_name>Michel F. Levesque, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

